glp-1 approved for type 1 diabetes Drugs and Diabetes: Less Insulin, Better Time in Range — What the Evidence SGLT2i and GLP-1 RA therapy

Lets break down why people switch, what to consider before changing, and how dosing usually works when you transition from one medication to another

Many people also noticed appetite suppression earlier in their treatment course compared to Semaglutide

(Waldner 2006) A double-blind RCT (n=30) in patients receiving high-dose interleukin-2 therapy reported a reduction in serious cardiac events (e.g., arrhythmias and acute heart failure) with L-carnitine use compared to no therapy, but the small sample size and heterogeneity of the cancer types limit generalizability

Ultimately, GLP-1based adjunct therapy in type 1 diabetes should be viewed as a personalized option rather than a standard treatment

Jeong WY, Kwon M, Choi HE, Kim KS